Fertility drugs not linked to uterine cancer recurrence

Share this article:
Fertility Drugs Not Linked to Uterine Cancer Recurrence
Fertility Drugs Not Linked to Uterine Cancer Recurrence

(HealthDay News) -- For women who undergo fertility-sparing treatment for uterine cancer, subsequent use of fertility drugs is not associated with a higher incidence of cancer recurrence, according to research published in the January issue of Obstetrics & Gynecology.

Jeong-Yeol Park, M.D., Ph.D., from the University of Ulsan College of Medicine in Seoul, South Korea, and colleagues examined pregnancy outcomes based on a review of the medical records of 141 women with stage IA, grade 1 endometrioid adenocarcinoma of the uterus who had complete remission after fertility-sparing management using progestin.

Of the cohort, 38.3 percent had a history of infertility. After treatment, the median interval to attempted pregnancy was five months, and at the time of the pregnancy trial, the median age was 32.4 years. The researchers found that 60 women (49.6 percent) tried to conceive, of which 62.9 percent received fertility drugs. Of the women who tried to conceive, 73 percent were successful and 66 percent gave birth (46 women to 58 live neonates). The spontaneous abortion rate was 24 percent, ectopic pregnancy rate 2.8 percent, and preterm delivery rate 11.5 percent. Women who did versus did not receive fertility drugs had similar five-year disease-free survival (73 versus 62 percent; P = 0.335), and for women who achieved at least one pregnancy, this rate was even higher compared to those who did not achieve pregnancy (76 versus 62 percent; P = 0.028).

"The use of fertility drugs was not associated with a higher incidence of cancer recurrence after successful fertility-sparing management in this study population," the authors write.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

ACCR: Oral olaparib with chemotherapy beneficial for ovarian cancer

ACCR: Oral olaparib with chemotherapy beneficial for ovarian ...

Olaparib has been deemed safe in combination with carboplatin/paclitaxel in advanced ovarian cancer.

Meta-Analysis: Prediabetes tied to increased risk of cancer

Meta-Analysis: Prediabetes tied to increased risk of cancer

Prediabetes has been linked to an increased risk of cancer overall and with increased risks of site-specific cancers, including liver, endometrial, and stomach/colorectal cancer.

Joint ASCO/CCO guidelines for advanced prostate cancer issued

Joint ASCO/CCO guidelines for advanced prostate cancer issued

Recommendations are for men whose tumors have grown resistant to hormonal therapies were issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) in Canada.